Sugi Predict

Sugi Predict / Compounds / SCHEMBL931908

SCHEMBL931908

SCHEMBL931908

COc1cccc2ccn(S(=O)(=O)c3ccccc3)c12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 13/20 0.62
▸ FABP4 P15090 1/20 0.59
▸ PPARG P37231 1/20 0.54
▸ PPARD Q03181 1/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ HPGD P15428 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ POLB P06746 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ PDE4A P27815 1/20 0.49
▸ PDE4B Q07343 1/20 0.49
▸ PDE4C Q08493 1/20 0.49
▸ PDE4D Q08499 1/20 0.49
▸ CYP2C19 P33261 1/20 0.48
▸ GAA P10253 2/20 0.45
▸ GFER P55789 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12359757 0.89 PPARG (0.55) HTR6FABP4PPARGPPARDMEN1
SCHEMBL30229407 0.80 HTR6 (0.58) HTR6PPARGPPARDMEN1KMT2A
SCHEMBL14727085 0.80 HTR6 (0.58) HTR6PPARGPPARDMEN1KMT2A
SCHEMBL5243831 0.79 HTR6 (0.56) HTR6FABP4MEN1KMT2AALDH1A1
SCHEMBL5242040 0.79 HTR6 (0.68) HTR6
SCHEMBL27901301 0.79 HTR6 (0.53) HTR6PPARGPPARDMEN1KMT2A
SCHEMBL5243644 0.79 HTR6 (0.47) HTR6MEN1KMT2AALDH1A1LMNA
Hydrochloric Acid SCHEMBL5243171 0.79 HTR6 (0.67) HTR6
Hydrochloric Acid SCHEMBL5652927 0.79 HTR6 (0.55) HTR6FABP4MEN1KMT2AALDH1A1
SCHEMBL30184484 0.78 HTR6 (0.60) HTR6MEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111225915-B Imidazopyridine compounds as PAD inhibitors 朱比兰特埃皮帕德有限公司 2023-03-07 — — CN disclosed
EP-3697785-B1 IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS Jubilant Epipad LLC (US) 2022-12-28 — — EP disclosed
EP-3697785-B1 IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS Jubilant Epipad LLC (US) 2022-12-28 — — EP disclosed
US-11426412-B2 Imidazo-pyridine compounds as PAD inhibitors Jubilant Epipad LLC (US) 2022-08-30 — — US disclosed
EP-3697785-A1 IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS Jubilant Epipad LLC (US) 2020-08-26 — — EP disclosed
US-20200237771-A1 IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS Jubilant Epipad LLC 2020-07-30 — — US disclosed
US-20200237771-A1 IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS Jubilant Epipad LLC 2020-07-30 — — US disclosed
CN-111225915-A Imidazopyridine compounds as PAD inhibitors 朱比兰特埃皮帕德有限公司 2020-06-02 — — CN disclosed
US-20190144398-A1 METHOD FOR TREATING INFLAMMATORY DISORDERS SYNTA PHARMACEUTICALS CORP. 2019-05-16 — — US disclosed
US-20190144398-A1 METHOD FOR TREATING INFLAMMATORY DISORDERS SYNTA PHARMACEUTICALS CORP. 2019-05-16 — — US disclosed
US-20080004276-A1 Method for treating non-hodgkin's lymphoma LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2008-01-03 — — US disclosed
US-20080004276-A1 Method for treating non-hodgkin's lymphoma LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2008-01-03 — — US disclosed
WO-2007140002-A2 METHOD FOR TREATING NON-HODGKIN'S LYMPHOMA SYNTA PHARMACEUTICALS CORP. (US) 2007-12-06 — — WO disclosed
WO-2007139951-A2 METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH PROTOONCOGENE PRODUCTS SYNTA PHARMACEUTICALS CORP. (US) 2007-12-06 — — WO disclosed
WO-2007139951-A2 METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH PROTOONCOGENE PRODUCTS SYNTA PHARMACEUTICALS CORP. (US) 2007-12-06 — — WO disclosed
WO-2007140002-A2 METHOD FOR TREATING NON-HODGKIN'S LYMPHOMA SYNTA PHARMACEUTICALS CORP. (US) 2007-12-06 — — WO disclosed
EP-1817295-A1 TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY Synta Pharmaceuticals Corporation (US) 2007-08-15 — — EP disclosed
WO-2006055760-A9 TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY SYNTA PHARMACEUTICALS CORP (US) 2006-09-21 — — WO disclosed
US-20060167070-A1 heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2006-07-27 — — US disclosed
WO-2006055760-A1 TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY SYNTA PHARMACEUTICALS CORP. (US) 2006-05-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200237771-A1 IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS PADI4, PADI1, PADI2 HTR6 3562/4885FABP4 1540/4885PPARG 160/4885
US-20080004276-A1 Method for treating non-hodgkin's lymphoma HSP90AB1, HSP90AB2P, HSP90B1 HTR6 2807/4885FABP4 2651/4885PPARG 1766/4885
US-20190144398-A1 METHOD FOR TREATING INFLAMMATORY DISORDERS TNF, IL2, IL5 HTR6 2388/4885FABP4 866/4885PPARG 525/4885
US-11426412-B2 Imidazo-pyridine compounds as PAD inhibitors PADI4, PADI1, PADI2 HTR6 3562/4885FABP4 1540/4885PPARG 160/4885
US-20060167070-A1 heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer HSP90AB1, HSP90AB2P, HSP90AA1 HTR6 3668/4885FABP4 3127/4885PPARG 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.